You are here

Alnylam

Will 2016 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?

Motley Fool

Mon, 12/14/15 - 10:16 pm

The 'Soliris-killer' cometh? Alnylam plans final 2017 trials to take on world's priciest drug

BioPharma Dive

Fri, 12/11/15 - 10:58 am

Alnylam Going After World's Most Expensive Drug in New Trials

Bloomberg

Thu, 12/10/15 - 10:29 am

Alnylam’s hemophilia drug appears to lower frequency of bleeding in early study

Bizjournals.com

Mon, 12/7/15 - 12:13 pm

Rewriting Pharma's Broken Social Contract: Q&A With Alnylam CEO John Maraganore

Forbes

Tue, 11/17/15 - 09:16 am

Why Amgen, Inc Should Acquire Alnylam

Bidness, ETC

Thu, 11/12/15 - 09:25 am

Medicines Company

What Companies Amgen May Be Eyeing For M&A?

Bidness, ETC

Tue, 11/10/15 - 08:29 am

Seattle Genetics

Sanofi steps deeper into RNAi work, opts in on Alnylam hemophilia drug

Fierce Biotech

Fri, 10/2/15 - 04:53 pm

Trial suggests Alnylam's cholesterol-lowering drug may last longer than Amgen's

Bizjournals.com

Sun, 08/30/15 - 02:04 pm

The Medicines Company

PCSK9 inhibitors

5 Biotech Stocks On Deck With The FDA

Yahoo/Benzinga

Tue, 06/30/15 - 06:13 pm

Esperion Therapeutics

Intercept Pharmaceuticals

obeticholic acid

Sarepta Therapeutics

What's The Street Think Of Alnylam Pharmaceuticals New Drug Data?

Yahoo/Benzinga

Thu, 06/25/15 - 09:03 am

Alnylam reports 1Q loss

Yahoo/AP

Mon, 05/11/15 - 10:59 am

Alnylam's star RNAi drug keeps the pace on the way to Phase III

Fierce Biotech

Tue, 04/21/15 - 12:20 pm

It's A Big Weekend For Biotech

Yahoo/Benzinga

Sat, 04/18/15 - 11:55 am

PTC Therapeutics

Bristol-Myers Squibb

Juno Therapeutics

The Biotech Selloff: It’s Déjà Vu All Over Again

Barron's

Thu, 03/26/15 - 10:13 am

Isis Pharmaceuticals

Vertex Pharmaceuticals

Novartis sells its RNAi cast-offs from Alnylam in $35M fire sale to Arrowhead

Fierce Biotech

Thu, 03/5/15 - 08:21 am

Arrowhead Research

Booming biotechs bank $2.7B in follow-on cash

Fierce Biotech

Fri, 01/23/15 - 03:38 pm

Puma Biotechnology

Arena Pharmaceuticals

With $450M sale, Alnylam has more cash than any pre-commercial biotech

Bizjournals.com

Tue, 01/20/15 - 02:00 pm

Alnylam reports results from Phase 2 revusiran trial

Seeking Alpha

Fri, 11/14/14 - 09:54 am

TTR cardiac amyloidosis

Alnylam Drug Scores Against Rare Nerve Disease

Investors.com

Mon, 10/13/14 - 04:02 pm

familial amyloid polyneuropathy

Pages